Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
AC Immune
ISIN CH0329023102
|WKN A2AR5F
Market cap (in EUR)
298 m
Country
Switzerland
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Switzerland
Financials
Key metrics
| Market capitalisation, EUR | 298 m |
| EPS, EUR | -0.76 |
| P/B ratio | 4.0 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 29 m |
| Net income, EUR | -53 m |
| Profit margin | -186.44% |
What ETF is AC Immune in?
There is 1 ETF which contains AC Immune.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.03% | Equity United States Health Care Biotech | 44 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.